How to Choose Between Lemborexant and Daridorexant for Adult Insomnia
How should clinicians use this indirect comparison to choose between lemborexant and daridorexant for adults with insomnia?
Adults with insomnia may need pharmacotherapy when nonpharmacologic treatment is unavailable, insufficient, or not enough on its own. This guide applies when a clinician is considering a dual orexin receptor antagonist and wants a structured way to weigh likely benefit against common adverse effects using the article's NNT, NNH, and LHH findings.
-
Confirm that a DORA comparison is the decision at hand
Use this workflow only when choosing between lemborexant and daridorexant for adult patients with insomnia characterized by sleep onset and/or sleep maintenance difficulty. The article frames both agents as approved options for adults and positions NNT, NNH, and LHH as tools to inform decision-making when direct head-to-head trial data are unavailable.
-
Anchor the benefit side on subjective insomnia outcomes
If the clinical priority is maximizing the likelihood of symptomatic improvement, focus first on the reported NNTs for ISI and subjective total sleep time. In pooled month 1 data, lemborexant 5 mg and 10 mg had NNT values versus placebo less than 10 for ISI score less than 10, ISI score 7 or lower, ISI score improvement of at least 6 points, and sTST improvement greater than 80 minutes, whereas pooled daridorexant 25 mg and 50 mg had no NNT values versus placebo less than 10.
-
Use objective short-term sleep data to refine the choice
If objective short-term sleep maintenance is especially important, review the month 1 PSG findings. Lemborexant showed particularly robust month 1 benefit for at least 50% WASO improvement from baseline, with NNT of 5 for both 5 mg and 10 mg in SUNRISE 1, while PSG-based LPS improvement was described as having similar NNT ranges between lemborexant and daridorexant.
-
Weigh common sedating adverse effects separately from efficacy
If minimizing somnolence or fatigue is a dominant concern, shift to the NNH results at month 3. Pooled daridorexant 25 mg and 50 mg had NNH of 49 for fatigue and 85 for somnolence, compared with pooled lemborexant NNH of 29 for fatigue and 12 for somnolence, indicating a more favorable indirect tolerability profile for daridorexant for these outcomes.
-
Interpret discontinuation risk with caution
Do not overread discontinuation due to adverse events as a definitive differentiator. For pooled daridorexant studies, placebo had higher discontinuation rates than active treatment, producing negative NNH values and an imputed NNH of 1,000 for LHH calculations; for pooled lemborexant at month 3, the NNH for discontinuation due to any adverse event was 52 and not statistically significant.
-
Use LHH to summarize the tradeoff for the patient in front of you
When you need a single summary of benefit-risk balance, use the article's LHH framing. For both drugs, LHH values were greater than 1 for the outcomes examined, meaning benefit was more likely than harm, but daridorexant had more favorable LHH values for discontinuation and sedating adverse effects, whereas lemborexant generally had more robust efficacy NNTs.
-
Temper any cross-drug conclusion by trial differences
Before applying the comparison directly to an individual patient, check whether that patient resembles the trial populations. The article notes important heterogeneity across studies, including SUNRISE 1 enrolling older adults with ISI at least 13 and no required sleep onset difficulty, while daridorexant trials enrolled adults 18 years or older with ISI at least 15 and a history of subjective sleep onset latency of at least 30 minutes; the authors therefore caution against definitive comparative claims.
Clinical Considerations
- This was an indirect comparison across different trials rather than a head-to-head randomized comparison.
- Study populations differed meaningfully, including age eligibility, baseline ISI thresholds, sleep-onset entry criteria, and baseline LPS.
- Some outcomes could not be compared because corresponding dichotomous data were not available for all agents and all measures.
- Short trial durations and strict eligibility criteria limit generalizability to real-world patients and may miss delayed or uncommon adverse events.
Bottom Line
Use lemborexant when stronger likelihood of subjective insomnia benefit is the priority and daridorexant when avoiding somnolence and fatigue is the priority, while recognizing that this tradeoff comes from indirect rather than head-to-head evidence.
